Drug intelligence / Profile preview

BHB-VH

Development stage: Preclinical
Lead developer: BigHat Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BHB-VH is an investigational, preclinical-stage T-cell engager (TCE-plus) being developed by BigHat Biosciences for the treatment of oncology indications. Engineered using BigHat's AI-driven Milliner platform, BHB-VH is designed to redirect the cytotoxic activity of T cells against tumor cells. While the specific tumor-associated antigen target remains undisclosed, the therapeutic candidate utilizes a T-cell engager modality to bridge T lymphocytes and cancer cells, promoting immune-mediated tumor destruction.

Targets

CD3 (T-cell surface glycoprotein CD3)F10 (Factor Xa)CEACAM6

Beyond the preview

Go deeper on BHB-VH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHB-VH.

Explore the full profile